HK1207816A1 - A liquid formulation of long-acting insulin conjugate - Google Patents

A liquid formulation of long-acting insulin conjugate

Info

Publication number
HK1207816A1
HK1207816A1 HK15106482.5A HK15106482A HK1207816A1 HK 1207816 A1 HK1207816 A1 HK 1207816A1 HK 15106482 A HK15106482 A HK 15106482A HK 1207816 A1 HK1207816 A1 HK 1207816A1
Authority
HK
Hong Kong
Prior art keywords
long
liquid formulation
acting insulin
insulin conjugate
conjugate
Prior art date
Application number
HK15106482.5A
Other languages
English (en)
Chinese (zh)
Inventor
林亨奎
金賢煜
洪性熙
金玟永
裴城敏
權世昌
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of HK1207816A1 publication Critical patent/HK1207816A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK15106482.5A 2012-07-25 2015-07-07 A liquid formulation of long-acting insulin conjugate HK1207816A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20120081477 2012-07-25
PCT/KR2013/006673 WO2014017847A1 (en) 2012-07-25 2013-07-25 A liquid formulation of long-acting insulin conjugate

Publications (1)

Publication Number Publication Date
HK1207816A1 true HK1207816A1 (en) 2016-02-12

Family

ID=49997581

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106482.5A HK1207816A1 (en) 2012-07-25 2015-07-07 A liquid formulation of long-acting insulin conjugate

Country Status (21)

Country Link
US (1) US10987424B2 (ru)
EP (1) EP2877157B1 (ru)
JP (2) JP6385925B2 (ru)
KR (1) KR102088856B1 (ru)
CN (1) CN104519871B (ru)
AR (1) AR091902A1 (ru)
AU (1) AU2013293718B2 (ru)
BR (1) BR112015001457B1 (ru)
CA (1) CA2879976C (ru)
CY (1) CY1121356T1 (ru)
DK (1) DK2877157T3 (ru)
ES (1) ES2715326T3 (ru)
HK (1) HK1207816A1 (ru)
HU (1) HUE042246T2 (ru)
MX (1) MX369201B (ru)
PL (1) PL2877157T3 (ru)
PT (1) PT2877157T (ru)
RU (1) RU2670270C2 (ru)
TR (1) TR201903661T4 (ru)
TW (2) TWI605824B (ru)
WO (1) WO2014017847A1 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10842951B2 (en) 2010-01-12 2020-11-24 Aerami Therapeutics, Inc. Liquid insulin formulations and methods relating thereto
US20160243199A1 (en) * 2015-02-25 2016-08-25 Dance Biopharm, Inc. Liquid insulin formulations and methods relating thereto
US9180261B2 (en) 2010-01-12 2015-11-10 Dance Biopharm Inc. Preservative free insulin formulations and systems and methods for aerosolizing
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
BR112016016578A2 (pt) 2014-01-20 2017-10-03 Hanmi Pharm Ind Co Ltd Insulina de ação prolongada e uso daanálogo de insulina, polinucleotídeo, vetor de expressão, transformante, insulina de ação prolongada bem como seu método de preparação e formulação da mesma, conjugado, e uso do mesmo mesma
CA2944138C (en) * 2014-03-31 2023-06-20 Hanmi Pharm. Co., Ltd. Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及glp-1/昇糖素雙重促效劑之治療糖尿病之組成物
KR20160101702A (ko) * 2015-02-17 2016-08-25 한미약품 주식회사 지속형 인슐린 또는 이의 아날로그 결합체
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
WO2017052329A1 (en) * 2015-09-24 2017-03-30 Hanmi Pharm. Co., Ltd. Protein complex by use of a specific site of an immunoglobulin fragment for linkage
CN105597087B (zh) * 2016-01-06 2019-04-26 山东新时代药业有限公司 一种甘精胰岛素注射液及其制备方法
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
EP3517544A4 (en) 2016-09-23 2020-06-03 Hanmi Pharm. Co., Ltd. INSULIN ANALOG HAVING REDUCED INSULIN RECEPTOR BINDING FORCE AND USE THEREOF
EP3604328A4 (en) * 2017-03-23 2021-01-06 Hanmi Pharm. Co., Ltd. REDUCED INSULIN ANALOGUE COMPLEX FOR INSULIN RECEPTOR AND ITS USE
WO2019066603A1 (ko) * 2017-09-29 2019-04-04 한미약품 주식회사 효력이 향상된 지속성 단백질 결합체
CN112969449A (zh) 2018-06-15 2021-06-15 费灵有限公司 特利加压素组合物及其用途
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
UY39099A (es) * 2020-02-27 2021-08-31 Aic246 Gmbh & Co Kg 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmacéuticas del mismo
AR127619A1 (es) 2021-11-15 2024-02-14 Lilly Co Eli FORMULACIONES CONSERVADAS DE FUSIONES DE INSULINA-Fc

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
CZ306180B6 (cs) 2000-12-07 2016-09-14 Eli Lilly And Company GLP-1 fúzní proteiny
US20060183197A1 (en) * 2001-01-11 2006-08-17 Andersen Kim V Variant growth hormone molecules conjugated with macromolecules compounds
US6737401B2 (en) * 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
AU2004210679A1 (en) * 2003-02-10 2004-08-26 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
JP4870569B2 (ja) 2003-11-13 2012-02-08 ハンミ ホールディングス カンパニー リミテッド 免疫グロブリン断片を用いた蛋白質結合体およびその製造方法
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
WO2006076471A2 (en) 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
WO2008116103A2 (en) * 2007-03-22 2008-09-25 Imclone Llc Stable antibody formulations
UA97673C2 (ru) * 2007-07-10 2012-03-12 Эли Лилли Энд Компани КОМПОЗИЦИЯ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА GLP-1Fc
EP3461496B1 (en) 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
RU2682720C2 (ru) * 2010-01-19 2019-03-21 Ханми Сайенс Ко., Лтд. Жидкие составы для конъюгата эритропоэтина длительного действия
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101324828B1 (ko) 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
KR101330868B1 (ko) 2010-06-08 2013-11-18 한미사이언스 주식회사 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체
KR101337797B1 (ko) * 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada

Also Published As

Publication number Publication date
JP6385925B2 (ja) 2018-09-05
TW201803587A (zh) 2018-02-01
CA2879976C (en) 2023-03-07
CN104519871B (zh) 2018-07-20
KR20140015207A (ko) 2014-02-06
CY1121356T1 (el) 2020-05-29
BR112015001457A2 (pt) 2017-07-04
DK2877157T3 (en) 2019-03-25
US20150196643A1 (en) 2015-07-16
ES2715326T3 (es) 2019-06-03
CA2879976A1 (en) 2014-01-30
AU2013293718A1 (en) 2015-02-12
JP2018119005A (ja) 2018-08-02
RU2670270C2 (ru) 2018-10-22
TR201903661T4 (tr) 2019-04-22
BR112015001457A8 (pt) 2018-01-23
AU2013293718B2 (en) 2018-05-10
US10987424B2 (en) 2021-04-27
BR112015001457B1 (pt) 2023-02-28
JP2015524428A (ja) 2015-08-24
JP6682570B2 (ja) 2020-04-15
TWI605824B (zh) 2017-11-21
EP2877157A1 (en) 2015-06-03
PL2877157T3 (pl) 2019-06-28
EP2877157B1 (en) 2018-12-12
HUE042246T2 (hu) 2019-06-28
TW201412328A (zh) 2014-04-01
PT2877157T (pt) 2019-03-22
RU2015104495A (ru) 2016-09-10
MX369201B (es) 2019-10-30
EP2877157A4 (en) 2016-06-01
KR102088856B1 (ko) 2020-03-13
MX2015000988A (es) 2015-11-13
CN104519871A (zh) 2015-04-15
WO2014017847A1 (en) 2014-01-30
AR091902A1 (es) 2015-03-11

Similar Documents

Publication Publication Date Title
HK1207816A1 (en) A liquid formulation of long-acting insulin conjugate
HK1246190A1 (zh) 長效g-csf綴合物的液體製劑
HK1204565A1 (en) A liquid formulation of long acting insulinotropic peptide conjugate
HK1204291A1 (en) A liquid formulation of long-acting insulin and insulinotropic peptide
HK1212269A1 (en) Prefilled syringe
HK1208372A1 (en) Liquid formulation
EP2525779A4 (en) LIQUID FORMULATIONS FOR A ERYTHROPOIETIN CONJUGATE WITH LONG-TERM EFFECT
IL238651A0 (en) Long-acting, single-chain insulin analogs
EP2695630A4 (en) LIQUID INFUSION INSTRUMENT
EP2724740A4 (en) SYRINGE
EP2830649A4 (en) LIQUID FORMULATION FROM A HIGHLY CONCENTRATED AND LONG-ACTING HUMAN GROWTH HORMONE CONJUGATE
HK1205683A1 (en) Pharmaceutical formulation having improved stability
EP2875837A4 (en) LIQUID ADMINISTRATION TOOL
HK1207296A1 (en) Genotype- or phenotype-based drug formulation
EP2908849A4 (en) METHOD FOR ENHANCING THE PHARMACOKINETICS OF MEDICAMENTS
HK1204945A1 (en) Pharmaceutical formulation containing flupirtin
GB201213522D0 (en) Single use syringe
GB201213521D0 (en) Single use syringe